Histological and cytogenetic characterization of bone marrow in relation to prognosis and diagnosis of myelodysplastic syndromes

Pathology International
Toshiko SakumaSakan Maeda

Abstract

Bone marrow (BM) histology of 102 myelodysplastic syndromes (MDS) patients was analyzed retrospectively. All the cases were reclassified according to the World Health Organization (WHO) classification. Karyotype study was conducted for all except one. Fifteen of the MDS cases were hypoplastic. The cellularity in bone marrow histology is sometimes ineffective in the differential diagnosis of MDS and aplastic anemia (AA). Nonetheless, a marked decrease in the number of megakaryocytes (average, 0.3/mm(2); range, 0-2/mm(2)) even in the hyperplastic foci of the marrow of AA was the most important histological feature differentiating AA from MDS, whereas the number of megakaryocytes increased in most MDS cases (44/mm(2); range, 1-240/mm(2)) and also in hypoplastic MDS (14/mm(2); range, 8-26/mm(2)). Hyperplastic marrow had a significantly high frequency of progress to acute myeloid leukemia (AML) and hypoplastic MDS had a lower rate of progress to AML. Severe myelofibrosis had a significantly poor prognosis. An increase in CD34-positive cells in MDS indicated a high rate of progress to AML. As for the patients with refractory cytopenia with multilineage dysplasia (RCMD; the new category under the WHO classification), the increased num...Continue Reading

References

Jan 1, 1989·Virchows Archiv. B, Cell Pathology Including Molecular Pathology·M KitagawaT Kasuga
Sep 1, 1988·Cancer·S Nand, J E Godwin
Jul 1, 1988·Journal of Clinical Pathology·Y YoshidaT Maekawa
Jul 1, 1971·American Journal of Clinical Pathology·D E Bauermeister
Sep 1, 1981·British Journal of Haematology·C SultanF Reyes
Aug 1, 1994·Leukemia Research·N Tuzuner, J M Bennett
Nov 1, 1995·British Journal of Haematology·N TuzunerJ M Bennett
Mar 11, 1999·Cytogenetics and Cell Genetics·S M PurandareP I Patel
May 26, 1999·The New England Journal of Medicine·M L Heaney, D W Golde
Nov 30, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N L HarrisC D Bloomfield
Feb 9, 2000·Der Pathologe·A Schmitt-GraeffM Lübbert
Jun 21, 2005·Medical Oncology·Dragomir MarisavljevicMilica Colovic

❮ Previous
Next ❯

Citations

Apr 12, 2008·World Journal of Pediatrics : WJP·Jin-Quan WenJu-Ping Pang
Jun 30, 2018·European Journal of Haematology·Uri GreenbaumMoshe Mittelman
Apr 30, 2017·Expert Review of Hematology·Prajwal Chaitanya Boddu, Tapan Mahendra Kadia

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.